Victrex (VCT) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
7 Jul, 2026Executive summary
Q3 revenues grew 18% year-over-year, with volumes up 17%, reflecting continued momentum from Q2, especially in Sustainable Solutions end markets.
Aerospace and Electronics divisions led growth, with Aerospace rebounding from prior year supply chain issues.
Medical segment showed signs of stabilisation, contributing to overall performance.
Financial highlights
Q3 revenue reached £84.5m, up from £71.5m in Q3 2025; sales volume was 1,238 tonnes, up from 1,057 tonnes.
Year-to-date (YTD) revenue increased 7% to £231.6m, with YTD volumes up 10% to 3,375 tonnes.
Average selling price (ASP) remained stable at £68/kg compared to the prior year.
Net debt at 30 June 2026 was £43.0m, with cash of £27.5m after paying a £12m interim dividend.
Outlook and guidance
Full-year guidance is maintained, with underlying profit before tax (PBT) expected in the range of £42m–£44m.
Initial cost savings from the Profit Improvement Plan will begin in Q4, with annualised savings of at least £10m expected to be fully realised in FY 2027.
Management remains cautious about seasonality and macroeconomic factors, including global demand and energy costs.
Latest events from Victrex
- Strong FY25 volumes and cash flow, with cost savings and China expansion driving future growth.VCT
Investor presentation - Growth driven by innovation in sustainable PEEK solutions and mega-programme commercialisation.VCT
Investor presentation - Targets c.50% gross margin and 75%+ free cash flow returns to shareholders by FY31.VCT
CMD 2026 - FY 2026 profit outlook raised on strong Q4 growth and cost savings, with strategic divestment completed.VCT
Trading update - Underlying profit fell 18% as China impairment and restructuring weighed on results.VCT
H1 2026 - Net zero by 2050, 53% revenue from sustainable products, and 40% female leadership achieved.VCT
ESG Presentation - 12% volume growth, strong cash flow, but profit down 21% on FX and China costs; GBP 10m savings plan.VCT
H2 2025 - Q3 volumes up 20% year-over-year, but Medical weakness persists amid industry destocking.VCT
Q3 2024 TU - 16% volume growth and strong cashflow drive upgraded FY25 outlook despite FX headwinds.VCT
H1 2025